Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
|Articles|September 2, 2011
Strategic Approach to Glycoprotein and Glycosylation Analysis Intertek and NIBRT Seminar
Intertek and NIBRT are pleased to announce two free seminars covering the Characterisation of Glycoproteins.
Advertisement
Intertek and NIBRT are pleased to announce two free seminars covering the Characterisation of Glycoproteins.
To request the agenda contact us now at
The presentations will be delivered by experts in their field; Ashleigh Wake Intertek’s Biotechnology Team Leader and Professor Pauline Rudd, a leading authority on protein glycosylation.
This seminar would be of interest to professionals working in protein therapeutic development and manufacturing.
Agenda:
- Introduction to the Intertek / NIBRT strategic collaboration
- A Strategic approach to glycoprotein analysis – Ashleigh Wake, Intertek Biotechnology Team Leader
- A systematic approach to protein glycosylation analysis – Prof. Pauline Rudd, NIBRT
Dates:
22nd September 2011, Intertek, Manchester, UK
23rd September 2011, NIBRT, Dublin, Ireland
Register your interest
Advertisement
Related to this article
Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
Univar Solutions scientists developed a lidocaine cream built on starch, sorbitol, coconut oil, and beeswax that matched a commercial benchmark on viscosity, assay, and hydration.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Formulation and Evaluation of a Sustainable Analgesic Cream Utilizing Renewable Bio-Based Ingredients and Green Chemistry Design Principles
2
Nitrosamine Problems and Industry Solutions: PharmTech Explained
3
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
4
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
5